These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 32297279)

  • 1. Feasibility and Outcome of a Phase II Study of Intensive Induction Chemotherapy in 91 Elderly Patients with AML Evaluated Using a Simplified Multidimensional Geriatric Assessment.
    Capelli D; Saraceni F; Fiorentini A; Chiarucci M; Menotti D; Poloni A; Discepoli G; Leoni P; Olivieri A
    Adv Ther; 2020 May; 37(5):2288-2302. PubMed ID: 32297279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mobilization-driven postconsolidation therapy in elderly patients with acute myeloid leukemia: feasibility and efficacy of autologous stem cell transplantation versus low-dose gemtuzumab ozogamicin.
    Capelli D; Chiarucci M; Poloni A; Saraceni F; Mancini G; Trappolini S; Troiani E; Montanari M; Scortechini I; Offidani M; Rupoli S; Scortechini AR; Gini G; Discepoli G; Leoni P; Olivieri A
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1399-406. PubMed ID: 24880020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial.
    Candoni A; Papayannidis C; Martinelli G; Simeone E; Gottardi M; Iacobucci I; Gherlinzoni F; Visani G; Baccarani M; Fanin R
    Am J Hematol; 2018 May; 93(5):655-663. PubMed ID: 29396857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patients.
    Olivieri A; Capelli D; Troiani E; Poloni A; Montanari M; Offidani M; Discepoli G; Leoni P
    Exp Hematol; 2007 Jul; 35(7):1074-82. PubMed ID: 17588476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
    Archimbaud E; Jehn U; Thomas X; De Cataldo F; Fillet G; Belhabri A; Peaud PY; Martin C; Amadori S; Willemze R
    Leukemia; 1999 Jun; 13(6):843-9. PubMed ID: 10360370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.
    Guolo F; Minetto P; Clavio M; Miglino M; Di Grazia C; Ballerini F; Pastori G; Guardo D; Colombo N; Kunkl A; Fugazza G; Rebesco B; Sessarego M; Lemoli RM; Bacigalupo A; Gobbi M
    Am J Hematol; 2016 Aug; 91(8):755-62. PubMed ID: 27084986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.
    Ravandi F; Assi R; Daver N; Benton CB; Kadia T; Thompson PA; Borthakur G; Alvarado Y; Jabbour EJ; Konopleva M; Takahashi K; Kornblau S; DiNardo CD; Estrov Z; Flores W; Basu S; Allison J; Sharma P; Pierce S; Pike A; Cortes JE; Garcia-Manero G; Kantarjian HM
    Lancet Haematol; 2019 Sep; 6(9):e480-e488. PubMed ID: 31400961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemtuzumab Ozogamicin in
    Schlenk RF; Paschka P; Krzykalla J; Weber D; Kapp-Schwoerer S; Gaidzik VI; Leis C; Fiedler W; Kindler T; Schroeder T; Mayer K; Lübbert M; Wattad M; Götze K; Horst HA; Koller E; Wulf G; Schleicher J; Bentz M; Greil R; Hertenstein B; Krauter J; Martens U; Nachbaur D; Abu Samra M; Girschikofsky M; Basara N; Benner A; Thol F; Heuser M; Ganser A; Döhner K; Döhner H
    J Clin Oncol; 2020 Feb; 38(6):623-632. PubMed ID: 31851556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).
    de Witte T; Suciu S; Meert L; Halkes C; Selleslag D; Bron D; Amadori S; Willemze R; Muus P; Baron F
    Ann Hematol; 2015 Dec; 94(12):1981-9. PubMed ID: 26410352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
    Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
    Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
    Malfuson JV; Konopacki J; Thepenier C; Eddou H; Foissaud V; de Revel T
    Ann Hematol; 2012 Dec; 91(12):1871-7. PubMed ID: 22820971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients.
    Brunnberg U; Mohr M; Noppeney R; Dürk HA; Sauerland MC; Müller-Tidow C; Krug U; Koschmieder S; Kessler T; Mesters RM; Schulz C; Kosch M; Büchner T; Ehninger G; Dührsen U; Serve H; Berdel WE
    Ann Oncol; 2012 Apr; 23(4):990-6. PubMed ID: 21810729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
    Liu H; Fu R; Li L; Wang G; Song J; Ruan E; Wang H; Wu Y; Wang X; Ding K; Shao Z
    Clin Drug Investig; 2017 Feb; 37(2):167-174. PubMed ID: 27722823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML.
    Bassan R; Intermesoli T; Masciulli A; Pavoni C; Boschini C; Gianfaldoni G; Marmont F; Cavattoni I; Mattei D; Terruzzi E; De Paoli L; Cattaneo C; Borlenghi E; Ciceri F; Bernardi M; Scattolin AM; Todisco E; Campiotti L; Corradini P; Cortelezzi A; Ferrero D; Zanghì P; Oldani E; Spinelli O; Audisio E; Cortelazzo S; Bosi A; Falini B; Pogliani EM; Rambaldi A
    Blood Adv; 2019 Apr; 3(7):1103-1117. PubMed ID: 30948365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia.
    Borlenghi E; Cattaneo C; Cerqui E; Archetti S; Bertoli D; Bellotti D; Gramegna D; Soverini G; Oberti M; Schieppati F; Pagani C; Passi A; Sciumé M; Farina M; Carbone C; Crippa C; Dalceggio D; Tucci A; Rossi G
    Hematol Oncol; 2020 Dec; 38(5):754-762. PubMed ID: 32950042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy.
    Chen Y; Yang T; Zheng X; Yang X; Zheng Z; Zheng J; Liu T; Hu J
    Medicine (Baltimore); 2016 Jul; 95(30):e4182. PubMed ID: 27472687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.
    Thomas X; Suciu S; Rio B; Leone G; Broccia G; Fillet G; Jehn U; Feremans W; Meloni G; Vignetti M; de Witte T; Amadori S
    Haematologica; 2007 Mar; 92(3):389-96. PubMed ID: 17339189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing cure rates for gemtuzumab ozogamicin plus standard chemotherapy vs standard chemotherapy alone in acute myeloid leukemia patients.
    Muresan B; Mamolo C; Cappelleri JC; Mokgokong R; Palaka A; Soikkeli F; Heeg B
    Future Oncol; 2021 Aug; 17(22):2883-2892. PubMed ID: 33858190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk.
    Tavor S; Rahamim E; Sarid N; Rozovski U; Gibstein L; Aviv F; Kirsner I; Naparstek E
    Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):438-43. PubMed ID: 23017331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia.
    Bergua JM; Montesinos P; Martinez-Cuadrón D; Fernández-Abellán P; Serrano J; Sayas MJ; Prieto-Fernandez J; García R; García-Huerta AJ; Barrios M; Benavente C; Pérez-Encinas M; Simiele A; Rodríguez-Macias G; Herrera-Puente P; Rodríguez-Veiga R; Martínez-Sánchez MP; Amador-Barciela ML; Riaza-Grau R; Sanz MA;
    Br J Haematol; 2016 Sep; 174(5):700-10. PubMed ID: 27118319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.